ArticleJournal of molecular neuroscience : MN2025
Comprehensive in Silico Reclassification of MECP2 Variants of Uncertain Significance in Rett Syndrome: Performance Evaluation and Structural Analysis.
Article in Journal of molecular neuroscience : MN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rett syndrome (RTT) is a severe neurodevelopmental disorder primarily caused by missense variants in the MECP2 gene. However, the presence of variants of uncertain significance (VUS) poses major challenges for clinical diagnosis and genetic counseling. In this study, we systematically evaluated the performance of 33 in silico prediction tools using a curated ClinVar dataset of MECP2 missense variants. Performance metrics included accuracy, sensitivity, specificity, area under the curve (AUC), and Matthews correlation coefficient (MCC), incorporating gene-specific pathogenicity thresholds to enhance predictive precision. Evolutionary conservation was assessed using ConSurf, while structural consequences were examined using UniProt, HOPE, DUET, PyMOL, and RING. Nine top-performing tools-MutPred, MetaRNN, REVEL, MutScore, SNPred, BayesDel, ClinPred, AlphaMissense, and DeepSAV-achieved accuracies exceeding 91% and correctly classified all 19 functionally validated pathogenic variants. These tools consistently predicted 15 VUS as pathogenic, with 14 located within the methyl-CpG-binding domain (MBD) and one within the NCOR2/SMRT interaction region; all occurred at highly conserved residues (ConSurf score: 9). Structural analyses revealed destabilizing effects through altered hydrophobicity, electrostatic charge, and residue interactions, implicating impaired DNA binding or disrupted co-repressor interactions. This integrative framework, combining high-performance computational prediction with structural modeling, offers a robust approach to reclassifying MECP2 VUS and supports improved diagnostic accuracy and personalized care in RTT.
Indexed as
Identifiers
41015588What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.